Skip to main content

Table 1 Relationship between IGFBP-3 expression and clinicopathology

From: Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome

Characteristic IGFBP-3 score P No. of patients
  Negative Weak (1+) Strong (2+)   
Invasive tumours 15 54 32   101*
   Age (years)      
≤ 50 1 13 13 0.04 27
> 50 14 41 19   74
   Lymph node status      
Negative 7 17 13 0.216 37
Positive 4 31 16   51
Not assessed      13
   IDC grade      
I 2 9 5 0.836 16
II 9 24 17   50
III 4 21 10   35
   IDC size      
≤ 2 cm 9 26 17 0.720 52
>2 cm 6 27 14   47
Multifocal      2
   LV invasion      
Absent 9 27 12 0.411 48
Present 6 26 18   50
Not assessed      3
   NPI      
GPG (< 3.4) 6 17 11 0.662 34
MPG (3.4–5.4) 4 19 13   36
PPG (> 5.4) 1 11 4   16
Not calculable      15
   ER (quick-score)      
Positive (4–8) 12 28 21 0.06 61
Negative (0–3) 2 24 9   35
Not assessed      7
   HER-2 IHC      
Negative (0/1+) 14 48 23 0.065 85
Positive (2+/3+) 1 6 9   16
   Ki67 IHC      
Low proliferation < 10% 10 26 13 0.249 49
High proliferation ≥ 10% 5 28 19   52
DCIS      102*
   VNPC      
Grade I 1 14 8 0.586 23
Grade II 5 17 14   36
Grade III 2 21 15   38
Not assessed      5
   ER (quick-score)      
Positive (4–8) 11 26 19 0.037 56
Negative (0–3) 1 23 9   33
Not assessed      13
   HER-2 IHC      
Negative (0/1+) 7 41 28 0.876 76
Positive (2+/3+) 2 9 8   19
Not assessed      7
   Ki67 IHC      
Low proliferation < 10% 6 30 24 0.972 60
High proliferation ≥ 10% 4 22 16   42
  1. DCIS, ductal carcinoma in situ; ER, oestrogen receptor; GPG, good prognostic group; IHC, immunohistochemistry; MPG, moderate prognostic group; NPI, Nottingham Prognostic Index; PPG, poor prognostic group; VNPC, Van Nuys Pathologic classification. Significant P values (P < 0.05) are indicated in bold.
  2. *Patient numbers reflect those in whom IGFBP-3 was evaluable.